ストックスクリーナーアプリを入手
1.59
3.05%
-0.05
前日終値:
$1.64
開ける：
$1.65
24時間の取引高:
68,275
Relative Volume:
0.30
時価総額：
$30.92M
収益：
-
当期純損益:
$-33.08M
株価収益率:
-0.5408
EPS:
-2.94
ネットキャッシュフロー:
$-25.68M
1週間 パフォーマンス:
-8.62%
1か月 パフォーマンス:
-2.45%
6か月 パフォーマンス:
+93.90%
1年 パフォーマンス:
+218.64%
1日の値動き範囲:
$1.55
$1.68
1週間の範囲:
$1.54
$1.79
52週間の値動き範囲:
$0.42
$2.55
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
名前
Chemomab Therapeutics Ltd Adr
セクター
電話
972-77-331-0156
住所
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
CMMB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CMMB | 1.59 | 30.92M | 0 | -33.08M | -25.68M | -2.94 |
| VRTX | 448.93 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.47 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.75 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.43 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Chemomab Therapeutics Ltd Adr (CMMB) 最新ニュース
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.
Chemomab reports progress in PSC treatment trial - Investing.com
Roth MKM Initiates Coverage of Chemomab Therapeutics LtdADR (CMMB) with Buy Recommendation - MSN
The Chemomab Therapeutics Ltd ADR (CMMB) had a good session last reading, didn’t it? - US Post News
Financial Health Check: Examining Chemomab Therapeutics Ltd ADR (CMMB)’s Key Ratios - The Dwinnex
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Ratios Uncovered: Breaking Down Chemomab Therapeutics Ltd ADR (CMMB)’s Trailing Twelve Months Metrics - The Dwinnex
Is Chemomab Therapeutics Ltd ADR (CMMB) a good investment opportunity? - US Post News
CMMB stock touches 52-week high at $2.07 amid market fluctuations - Investing.com
Chemomab Therapeutics Ltd ADR (CMMB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Are Chemomab Therapeutics Ltd ADR (CMMB) shares a good deal now? - US Post News
CMMB stock touches 52-week high at $1.58 amid market fluctuations - Investing.com India
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Market Analysts see American Express Co. [AXP] gaining to $265. Time to buy? - The DBT News
Chemomab Therapeutics Ltd ADR [CMMB] moved down -16.20: Why It’s Important - The DBT News
Chemomab regains Nasdaq compliance with bid price rule - Investing.com
Public Service Enterprise Group Inc. [PEG] Revenue clocked in at $9.72 billion, up 21.41% YTD: What’s Next? - The DBT News
Cerevel Therapeutics Holdings Inc [CERE] Is Currently 2.37 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Ardelyx Inc [ARDX] moved down -2.31: Why It’s Important - The DBT News
CMMB’s 2023 Market Dance: Up 107.84% – Time to Invest? - The InvestChronicle
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise - Benzinga
Chemomab secures $10 million in PIPE financing - Investing.com India
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? - Yahoo News Malaysia
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - MSN
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - Investing.com India
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update - Investing.com India
LGVN Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Why Copart, Inc. (CPRT) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire
Chemomab Stock: Leading Anti-CCL24 mAb For Fibrotic Diseases (NASDAQ:CMMB) - Seeking Alpha
Chemomab And AGC Biologics Partner To Manufacture CM-101 For Phase II/III - Contract Pharma
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
Chemomab Therapeutics (NASDAQ:CMMB) Stock Quotes, Forecast and News Summary - Benzinga
The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal - Yahoo Finance
Chemomab Therapeutics Ltd Adr (CMMB) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):